Novel approaches to modulate CAR-T cell function by targeting the tumor microenvironment in ovarian cancer

Area of Science:

• Oncology
• Immunotherapy
• Gynecologic Oncology

Background:

• Ovarian cancer (OC) has a poor prognosis, with a 5-year survival rate of ~30% for advanced stages, necessitating novel treatments.
• Chimeric antigen receptor T (CAR-T) cell therapy has transformed hematologic cancer treatment but faces hurdles in solid tumors like OC.
• The immunosuppressive tumor microenvironment (TME) of ovarian cancer significantly inhibits CAR-T cell function, limiting therapeutic potential.

Purpose of the Study:

• To investigate how ovarian cancer TME components impede CAR-T cell activity.
• To identify signaling pathways responsible for reduced CAR-T cell infiltration and persistence in ovarian tumors.
• To review strategies for overcoming TME-mediated immunosuppression in ovarian cancer CAR-T therapy.

Main Methods:

• Systematic review of literature on ovarian cancer TME immunosuppressive mechanisms.
• Analysis of cellular and molecular factors inhibiting CAR-T cell function in OC.
• Evaluation of advanced CAR engineering, combination therapies, and TME modulation techniques.

Main Results:

• The OC TME employs multifaceted immunosuppressive strategies that hinder CAR-T cell efficacy.
• Specific signaling patterns contribute to impaired CAR-T cell infiltration and survival within the tumor.
• Next-generation CAR designs and TME-targeting approaches show potential to enhance CAR-T cell activity.

Conclusions:

• Overcoming the immunosuppressive OC TME is critical for successful CAR-T cell therapy.
• Innovative strategies are essential to translate CAR-T therapy into a viable treatment for ovarian cancer.
• This review provides a roadmap for advancing CAR-T cell therapy in ovarian cancer, addressing an urgent unmet need.